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First reference by Morgagni in 1748 
- In 1938, described by Henry Turner  
Most common sex chromosome abnormality in females.  
Loss of part or all of an X 
chromosome 
Occurs in approximately 1 in 2.500 live births. 
Heny H. Turner 
INTRODUCTION – TURNER SYNDROME 
• The most characteristic features are: short stature and 
primary amenorrhea in young woman. 
 
• Other features: 
 
CLINICAL CASE 
• 65 year old woman, factory worker. 
 
• Referred to Endocrinology’s outpatient clinic by her new 
general physician because of short stature and primary 
amenorrhea. 
CLINICAL CASE 
• Personal medical history: 
- DM2, diagnosed 20 years ago, hypertension, hypoacusia 
(use of hearing aid) and hypothyroidism. 
 
• Usual medication: 
- Sitagliptin/Metformin 50/1000 mg bid, Lisinopril 10 mg 
and Levothyroxine 75 mg. 
 
• No relevant family history. 
 
CLINICAL CASE 
• Physical examination: 
 
Height – 134 cm 
Weight – 40,5 kg  
BP – 127/78 mm hg 
No thelarhe. No nevi. 
Cardiac A. – s1+s2 rhythmic 




VALUE REFERENCE VALUE 
Hemoglobin 12.9 11.9-15.6 g/dL 
White blood count 8.4x103 4.0-11.0x103/uL 
Platelets 241x103 150-400x103/uL 
Creatinine 0.60 0.60-1.20 mg/dL 
AST (GOT) 14 15-37 U/L 
ALT (TGP) 27 12-78 U/L 
Cholesterol - Total 188 < 200 mg/dL 
Cholesterol - HDL 58 > 45 mg/dL 
Triglycerides 99 < 150 mg/dL 
Hba1c 10,0 3.4-5.8 % 
TSH 1.880 0.358-3.74 uUI/mL 
FSH 31.51 23.0-116.3 mUI/mL 
LH 7.18 15.9-54.0 mUI/mL 
Estradiol < 43.31 < 118.2 pmol/L 
DHEA-SO4 138.00 35-430 ug/dL 
4-Androstenediona 1.01 0.3-3.3 ng/mL 
Testosterone 12.90 14-76 ng/dL 
HLA DQ2 / DQ8 Negative 
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Intensified treatment with Insulin 
CLINICAL CASE 
Pelvic ecography revealed an uterus of small dimensions 
and the ovaries were not identified. 
 
Bone densitometry showed accentuated osteoporosis (T-
socre - 2.9 and Z-score -1,2) 
            started alendronic acid+colecalciferol 70 mg/5600U.  
 
ECG and echocardiogram were normal. 
 
Renal ultrasound with no abnormalities. 
  
CLINICAL CASE 
• Karyotype revealed mosaicism 45,X/46,XX 
DISCUSSION 
• Higher overall mortality, up to a threefold risk increase 
compared with the general population. 
 
• Yearly follow-up: physical examination, biochemical 
testing, screening for hearing loss and cardiovascular 
abnormalities. 
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